Laboratory of Molecular Pharmacology

We study the principles of signalling and regulation of neurotransmitter receptors

+ endocannabinoids, + cannabinoid receptor, + receptors coupled to G-proteins

Jaroslav Blahoš

Group leader

Jaroslav Blahoš

Scientific Career – Milestones

since 2007: Research Group Leader, IMG, Prague
2002: PhD, First Faculty of Medicine, Charles University, Prague
1996-2000: Postdoctoral Fellow, CNRS, Montpellier, France
1994-1996: Postdoctoral Fellow, NIDCD, NIH, Bethesda, USA
1990: MD, Second Faculty of Medicine, Charles University, Prague

Interaction of SGIP1 with cannabinoid receptor 1 (CB1R) in the brain

We have found that SGIP1 (SH3 domain GRB2-like endophilin-interacting protein 1) modifies the CB1R signalling pathway by interfering with internalization that follows CB1R activation. We also found that SGIP1, like CB1R, concentrates in presynaptic portions of neurons. [pubmed] [doi]

Regulation of the cannabinoid receptor CB1R in vivo by SGIP1

We have tested SGIP1 knockout mice in a battery of behavioural tests. The SGIP1−/− mice did not show changes in sensorimotor gating, exploratory levels, or working memory, but showed decreased anxiety-like symptoms. Our results suggest that the absence of SGIP1 leads to changes in certain behaviours induced by THC administration and CB1R activation. [pubmed] [doi]

Reduction of acute nociception in mice with SGIP1 deletion

We have found that SGIP1-/- mice are more sensitive to analgesics. Our results suggest that SGIP1 is involved in the regulation of emotionality, mood, and nociception and modulates in vivo signalling of CB1 cannabinoid receptors. [pubmed] [doi]

Additional information about group